<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01432717</url>
  </required_header>
  <id_info>
    <org_study_id>A536-02</org_study_id>
    <nct_id>NCT01432717</nct_id>
  </id_info>
  <brief_title>Study of ACE-536 in Healthy Postmenopausal Women</brief_title>
  <official_title>A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ACE-536 in Healthy Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acceleron Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acceleron Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether ACE-536 can be safely given to patients.
      This study will also look to see if ACE-536 increases red blood cells, the cells that carry
      oxygen in the body.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events as a measure of safety and tolerability.</measure>
    <time_frame>22 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACE-536 serum concentration after single and multiple ascending doses.</measure>
    <time_frame>22 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin levels after single and multiple ascending doses.</measure>
    <time_frame>22 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>ACE-536</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assigned to 1 of 5 possible dosing groups.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACE-536</intervention_name>
    <description>Subjects receive a total of 2 subcutaneous doses of ACE-536 on Day 1 and Day 15.</description>
    <arm_group_label>ACE-536</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects receive a total of 2 subcutaneous doses of placebo on Day 1 and Day 15.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Postmenopausal women

          -  Body Mass Index (BMI) of 20 - 32 kg/m2.

        Key Exclusion Criteria:

          -  History of hypertension

          -  Subject has received any erythropoiesis stimulating agents (e.g., Epogen, Procrit,
             Aranesp, etc.) within 6 months prior to Day 1

          -  History of clinically significant cardiac, endocrine, hematologic, hepatic, immune,
             metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or
             other disease

          -  Surgery within 3 months (other than minor cosmetic surgery or minor dental procedures)

          -  Subject has received treatment with another investigational drug, or approved therapy
             for investigational use within 1 month prior to Day 1, or if the half-life of the
             previous product is known, within 5 times the half-life prior to Day 1, whichever is
             longer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Acceleron Investigative Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2011</study_first_submitted>
  <study_first_submitted_qc>September 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2011</study_first_posted>
  <last_update_submitted>November 5, 2012</last_update_submitted>
  <last_update_submitted_qc>November 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

